Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.38 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16744000 | 1.00 | MAPK1 (0.46) | MAPK1LMNACYP2C9CHRM4CHRM2 | |
| SCHEMBL14310687 | 1.00 | MAPK1 (0.46) | MAPK1LMNACYP2C9CHRM4CHRM2 | |
| SCHEMBL16727365 | 1.00 | MAPK1 (0.46) | MAPK1LMNACYP2C9CHRM4CHRM2 | |
| SCHEMBL25773521 | 1.00 | MAPK1 (0.46) | MAPK1LMNACYP2C9CHRM4CHRM2 | |
| SCHEMBL13243111 | 0.94 | LMNA (0.46) | MAPK1LMNACYP2C9CHRM4CHRM2 | |
| SCHEMBL23101821 | 0.88 | CYP2C9 (0.57) | MAPK1LMNACYP2C9CHRM4CHRM2 | |
| SCHEMBL756764 | 0.88 | CYP2C9 (0.57) | MAPK1LMNACYP2C9CHRM4CHRM2 | |
| SCHEMBL12463068 | 0.88 | CYP2C9 (0.57) | MAPK1LMNACYP2C9CHRM4CHRM2 | |
| SCHEMBL22631620 | 0.88 | CYP2C9 (0.57) | MAPK1LMNACYP2C9CHRM4CHRM2 | |
| SCHEMBL14424486 | 0.88 | CYP2C9 (0.57) | MAPK1LMNACYP2C9CHRM4CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230217826-A1 | LIGHT EMITTING ELEMENT AND POLYCYCLIC COMPOUND FOR THE SAME | SAMSUNG DISPLAY CO LTD (KR) | 2023-07-06 | — | — | US | disclosed |
| EP-3660023-B1 | THIENOPYRIMIDINEDIONE COMPOUNDS AS ACC INHIBITORS AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO LTD (CN) | 2023-03-08 | — | — | EP | disclosed |
| US-20220298133-A1 | OXIME COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | NXERA PHARMA UK LIMITED (GB) | 2022-09-22 | — | — | US | disclosed |
| US-11352342-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-06-07 | — | — | US | disclosed |
| US-20220048928-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
| US-11208396-B2 | Oxime compounds as agonists of the muscarinic M1 and/or M4 receptor | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-12-28 | — | — | US | disclosed |
| US-20210387969-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2021-12-16 | — | — | US | disclosed |
| US-11040998-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20210040067-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| US-10752610-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-08-25 | — | — | US | disclosed |
| US-7781455-B2 | Compounds | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | disclosed |
| EP-1371646-B1 | ARYL-SUBSTITUTED ALICYCLIC COMPOUND AND MEDICAL COMPOSITION COMPRISING THE SAME | DAINIPPON SUMITOMO PHARMA CO (JP) | 2010-05-19 | — | — | EP | disclosed |
| US-20090318694-A1 | Cross-Linked Amine Compounds and Agents for Pest Control | NIPPON SODA CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-7538111-B2 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2009-05-26 | — | — | US | disclosed |
| US-7538111-B2 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2009-05-26 | — | — | US | disclosed |
| WO-2009037719-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | LUPIN LIMITED (IN) | 2009-03-26 | — | — | WO | disclosed |
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| EP-1932844-A1 | BRIDGED CYCLIC AMINE COMPOUND AND PEST CONTROL AGENT | NIPPON SODA CO., LTD. (JP) | 2008-06-18 | — | — | EP | disclosed |
| US-20070231744-A1 | Holographic recording medium | KABUSHIKI KAISHA TOSHIBA (JP) | 2007-10-04 | — | — | US | disclosed |
| US-7176199-B2 | Aryl-substituted alicyclic compound and medical composition comprising the same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040998-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | MAPK1 2819/4885LMNA 4562/4885CYP2C9 452/4885 |
| US-20210040067-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | MAPK1 1367/4885LMNA 2831/4885CYP2C9 478/4885 |
| US-20220048928-A1 | MUSCARINIC RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | MAPK1 2377/4885LMNA 2166/4885CYP2C9 1533/4885 |
| US-20210387969-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | MAPK1 2288/4885LMNA 2874/4885CYP2C9 553/4885 |
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | MAPK1 790/4885LMNA 853/4885CYP2C9 1835/4885 |
| US-11352342-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | MAPK1 1367/4885LMNA 2831/4885CYP2C9 478/4885 |
| US-20230217826-A1 | LIGHT EMITTING ELEMENT AND POLYCYCLIC COMPOUND FOR THE SAME | NFE2L2, CRY1, CRY2 | MAPK1 631/4885LMNA 318/4885CYP2C9 1291/4885 |
| US-20220298133-A1 | OXIME COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | CHRM1, CHRM2, CHRM4 | MAPK1 1220/4885LMNA 3171/4885CYP2C9 432/4885 |
| US-11208396-B2 | Oxime compounds as agonists of the muscarinic M1 and/or M4 receptor | CHRM1, CHRM2, CHRM4 | MAPK1 1792/4885LMNA 3060/4885CYP2C9 356/4885 |
| US-20090318694-A1 | Cross-Linked Amine Compounds and Agents for Pest Control | CYCS, NPY1R, CYBB | MAPK1 364/4885LMNA 2109/4885CYP2C9 1012/4885 |
| US-10752610-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | MAPK1 1367/4885LMNA 2831/4885CYP2C9 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.